Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended June 30, 2026. The decision aligns with SEBI regulations and the company's Insider Trading Code, prohibiting transactions by promoters, directors, KMPs, insiders, and connected persons, including their immediate relatives. The specific date for the Board Meeting to approve these financial results will be announced later.

Shukra Pharmaceuticals Ltd has announced an Extra Ordinary General Meeting (EGM) to be held on July 6, 2026, via Video Conferencing. The primary agenda is to seek shareholder approval for a preferential issue of 46,43,000 Convertible Equity Warrants to promoters. This move is in accordance with SEBI (ICDR) Regulations, 2018, and other applicable laws. The meeting will also address other businesses as may be decided by the Board.

Shukra Pharmaceuticals Ltd's Board of Directors met on June 10, 2026, to approve seeking fresh shareholder approval for a preferential issue of 46,43,000 Convertible Equity Warrants. The original approval from November 1, 2025, lapsed due to timing issues. The issue price will be re-computed as per SEBI ICDR Regulations, not lower than ₹34 per warrant. The company will hold an EGM on July 6, 2026, to pass a special resolution. Ms. Rupal Patel has been appointed as Scrutinizer. The total issue size is approximately ₹16.51 crore at a revised price of ₹35.56 per warrant.

Shukra Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for June 10, 2026. The primary agenda item is to ratify a member's resolution from an Extra-Ordinary General Meeting held on November 1, 2025, concerning an allotment. This ratification is required by BSE as the allotment was not completed within 15 days of the in-principle approval received on January 9, 2026. The company also plans to approve a draft notice for a postal ballot to seek shareholder ratification for this allotment under SEBI (ICDR) Regulations.

Shukra Pharmaceuticals Ltd. has allotted 17,35,000 fully paid-up equity shares to Dakshesh Shah and Parshva Texchem India Private Limited (Promoters) upon conversion of warrants. The allotment was made for cash, with the company receiving ₹4,42,42,500. Consequent to this allotment, the paid-up equity capital increased from ₹43,78,79,440 to ₹43,96,14,440. The board also approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹0.01 per share.

Shukra Pharmaceuticals Ltd's board has recommended and declared a final dividend of ₹0.01 (1%) per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting. The board also approved the allotment of 17,35,000 equity shares to warrant holders Dakshesh Shah and Parshva Texchem India Private Limited, increasing the paid-up equity capital to ₹43,96,14,440. The meeting was held on May 7, 2026.

Shukra Pharmaceuticals Ltd. announced audited financial results for the quarter ended March 31, 2026. The Board recommended a final dividend of ₹0.01 (1%) per equity share for FY26, subject to shareholder approval. Additionally, the board approved the allotment of 17,35,000 fully paid-up equity shares to Dakshesh Shah and Parshva Texchem India Private Limited upon conversion of warrants, increasing the paid-up equity capital to ₹43,96,14,440.

Shukra Pharmaceuticals Ltd declared its financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the standalone and consolidated audited financial results. A final dividend of ₹0.01 (1%) per equity share has been recommended, subject to shareholder approval. Additionally, the board approved the allotment of 17,35,000 equity shares to warrant holders Dakshesh Shah and Parshva Texchem India Private Limited upon conversion of warrants, increasing the paid-up equity capital to ₹43,96,14,440.

Shukra Pharmaceuticals Ltd. reports no deviation or variation in the utilization of proceeds from its preferential issue of convertible warrants, as per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The funds raised, amounting to ₹3,94,65,500, are being utilized as per the objects mentioned in the Extra Ordinary General Meeting notice dated November 1, 2025. The audit committee has reviewed and confirmed the absence of any deviation.

Shukra Pharmaceuticals Ltd has announced that its Board of Directors will convene on May 7, 2026. The primary agenda includes considering and approving the audited financial results for the quarter and financial year ended March 31, 2026, along with the Auditor's Report. Additionally, the Board will discuss and recommend a final dividend for the financial year 2025-26.